Advertisement

Clinical Rheumatology

, Volume 37, Issue 5, pp 1281–1293 | Cite as

Predictive value of microRNA-132 and its target gene NAG-1 in evaluating therapeutic efficacy of non-steroidal anti-inflammatory drugs treatment in patients with ankylosing spondylitis

  • Tuan-Mao Guo
  • Yong Yan
  • Wei-Ning Cao
  • Qiang Liu
  • Hai-Yun Zhu
  • Lan Yang
  • Mai-Cang Gao
  • Yan-Li Xing
Original Article
  • 129 Downloads

Abstract

Ankylosing spondylitis (AS) is a common chronic rheumatic disorder, accompanied by the differential expression of various microRNAs (miRNAs) in patients suffering from the condition, some of which have the potential to serve as novel complementary AS biomarkers. During this study, AS patients were recruited in connection with our investigation into the correlation of microRNA-132 (miR-132) in peripheral blood and its target gene NAG-1 expressions in relation with the clinical efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) treatment in patients with AS. A total of 218 AS patients who had been previously treated with oral diclofenac sodium and were placed into either the response (n = 175) or non-response groups (n = 43) following a 16-week period of therapeutic evaluation. An additional 113 healthy patients were also recruited for the purposes of the study. AS patient peripheral blood samples were obtained at the 0th, 8th, and 16th week, with the corresponding samples of the healthy patients collected at week 0. The expressions of miR-132 and NAG-1 were detected by RT-qPCR and analyzed using a ROC curve for the elucidation of the diagnostic value of peripheral blood miR-132 expressions as well as their predictive value among AS patients undergoing NSAIDs treatment. The targeting relations of miR-132 and NAG-1 were validated by microRNA.org and luciferase assay. Greater levels of peripheral blood miR-132 expression were observed among AS patients prior to treatment, in comparison to the healthy patients in the study. Prior to treatment, the area under the miR-132 ROC curve (AUC) of AS patients was 0.965, with a critical point of 2.605. The sensitivity and specificity of miR-132 were 91.7 and 97.3%, respectively, in regard to the AS diagnostic clinical efficacy. In comparison with the non-response group, the miR-132 expression of patients in the response group exhibited descended levels while the mRNA expression of NAG-1 increased. The ROC results indicated that the AUC of miR-132 was 0.876 with its sensitivity and specificity observed to be 95.3 and 80.0%, respectively. The AUC of NAG-1 was 0.912 with its sensitivity and specificity observed to be 76.6 and 79.1%, respectively. In comparison with the high miR-132 expression group and the low NAG-1 mRNA expression group, significantly improved blood biochemistry indexes, sign indexes, blood indexes, and adverse reaction rate were observed among the low miR-132 expression group and the high NAG-1 mRNA expression group. The microRNA.org and luciferase assay revealed NAG-1 to be a target of miR-132. Based on the results of this study, it was concluded that the expressions of MiR-132 and NAG-1 could serve as biological markers in the prediction of the therapeutic efficiency of NSAID treatment in AS patients.

Keywords

Ankylosing spondylitis Clinical efficacy MicroRNA-132 NAG-1 Non-steroidal anti-inflammatory drugs 

Notes

Acknowledgments

We thank the reviewers for their critical comments.

Funding Information

This work was supported by The Project of Traditional Chinese Medicine Administration in 2013 (13-LC101), The Key Innovation Project of Xianyang Central Hospital in 2014 (2014-1), the Project of the Department of Science And Technology in Shaanxi Province (2014JM4115), the Project of Scientific and Technological Innovation Team of Spinal Degeneration of Xianyang in 2014 (2014-8), the Research Fund of Provincial Health Department in 2016 (2016D071), the Project of Xianyang Science and Technology Bureau in 2016 (2016K02-99), and the Key Innovation Project of Xianyang Central Hospital in 2017 (2017Z-07).

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Huang CH, Wei JC, Chang WC, Chiou SY, Chou CH, Lin YJ, Hung PH, Wong RH (2014) Higher expression of whole blood micro RNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration. J Rheumatol 41(6):1104–1111.  https://doi.org/10.3899/jrheum.130515 CrossRefPubMedGoogle Scholar
  2. 2.
    Stanek A, Cieslar G, Romuk E, Kasperczyk S, Sieron-Stoltny K, Birkner E, Sieron A (2010) Decrease in antioxidant status of plasma and erythrocytes from patients with ankylosing spondylitis. Clin Biochem 43(6):566–570.  https://doi.org/10.1016/j.clinbiochem.2009.12.019 CrossRefPubMedGoogle Scholar
  3. 3.
    Reveille JD, Weisman MH (2013) The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci 345(6):431–436.  https://doi.org/10.1097/MAJ.0b013e318294457f CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chen R, Wei Y, Cai Q, Duan S, Lin J, Fang M, Lv K, Cheng N, Sun S (2010) PADI4 gene polymorphism is not associated with ankylosing spondylitis in Chinese Han population. Scand J Immunol 72(5):449–453.  https://doi.org/10.1111/j.1365-3083.2010.02454.x CrossRefPubMedGoogle Scholar
  5. 5.
    Qian BP, Ji ML, Qiu Y, Wang B, Yu Y, Shi W, Luo YF (2016) Identification of serum miR-146a and miR-155 as novel noninvasive complementary biomarkers for ankylosing spondylitis. Spine (Phila Pa 1976) 41(9):735–742.  https://doi.org/10.1097/BRS.0000000000001339 CrossRefGoogle Scholar
  6. 6.
    Zhang YP, Zhang ZH, Liu W, Tan ST, Ju ZG, Zhang XL, Ji Y, Wang LC, Kyaw Z, Hasanov N, Zhu BB, Lu SP, Sun XW, Demir HV (2015) Nonradiative recombination--critical in choosing quantum well number for InGaN/GaN light-emitting diodes. Opt Express 23(3):A34–A42.  https://doi.org/10.1364/OE.23.000A34 CrossRefPubMedGoogle Scholar
  7. 7.
    Kim SK, Nam JW, Rhee JK, Lee WJ, Zhang BT (2006) miTarget: microRNA target gene prediction using a support vector machine. BMC Bioinformatics 7(1):411.  https://doi.org/10.1186/1471-2105-7-411 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ucar A, Vafaizadeh V, Jarry H, Fiedler J, Klemmt PA, Thum T, Groner B, Chowdhury K (2010) miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet 42(12):1101–1108.  https://doi.org/10.1038/ng.709 CrossRefPubMedGoogle Scholar
  9. 9.
    Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S (2005) A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A 102(45):16426–16431.  https://doi.org/10.1073/pnas.0508448102 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH, Impey S (2008) An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci U S A 105(26):9093–9098.  https://doi.org/10.1073/pnas.0803072105 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H (2009) MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 31(6):965–973.  https://doi.org/10.1016/j.immuni.2009.09.019 CrossRefPubMedGoogle Scholar
  12. 12.
    Maharshak N, Shenhar-Tsarfaty S, Aroyo N, Orpaz N, Guberman I, Canaani J, Halpern Z, Dotan I, Berliner S, Soreq H (2013) MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflamm Bowel Dis 19(7):1346–1353.  https://doi.org/10.1097/MIB.0b013e318281f47d CrossRefPubMedGoogle Scholar
  13. 13.
    Baek SJ, Wilson LC, Eling TE (2002) Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23(3):425–434.  https://doi.org/10.1093/carcin/23.3.425 CrossRefPubMedGoogle Scholar
  14. 14.
    Rosu OM, Ancuta C (2015) McKenzie training in patients with early stages of ankylosing spondylitis: results of a 24-week controlled study. Eur J Phys Rehabil Med 51(3):261–268PubMedGoogle Scholar
  15. 15.
    Simopoulos TT, Manchikanti L, Gupta S, Aydin SM, Kim CH, Solanki D, Nampiaparampil DE, Singh V, Staats PS, Hirsch JA (2015) Systematic review of the diagnostic accuracy and therapeutic effectiveness of sacroiliac joint interventions. Pain Physician 18(5):E713–E756PubMedGoogle Scholar
  16. 16.
    Lu KP, Alejandro NF, Taylor KM, Joyce MM, Spencer TE, Ramos KS (2002) Differential expression of ribosomal L31, Zis, gas-5 and mitochondrial mRNAs following oxidant induction of proliferative vascular smooth muscle cell phenotypes. Atherosclerosis 160(2):273–280.  https://doi.org/10.1016/S0021-9150(01)00581-0 CrossRefPubMedGoogle Scholar
  17. 17.
    Ward MM, Guthrie LC, Alba MI (2014) Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? Arthritis Rheumatol 66(9):2339–2343.  https://doi.org/10.1002/art.38705 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jennings F, Oliveira HA, de Souza MC, Cruz Vda G, Natour J (2015) Effects of aerobic training in patients with ankylosing spondylitis. J Rheumatol 42(12):2347–2353.  https://doi.org/10.3899/jrheum.150518 CrossRefPubMedGoogle Scholar
  19. 19.
    Song Y, Wang C, Chen H (2017) Functional limitation and associated factors in outpatients with ankylosing spondylitis in Southwest China. Clin Rheumatol 36(4):871–877.  https://doi.org/10.1007/s10067-017-3563-3 CrossRefPubMedGoogle Scholar
  20. 20.
    Eriksson JK, Jacobsson L, Bengtsson K, Askling J (2017) Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis 76(2):364–370.  https://doi.org/10.1136/annrheumdis-2016-209315 CrossRefPubMedGoogle Scholar
  21. 21.
    Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356.  https://doi.org/10.1056/NEJMoa012664 CrossRefPubMedGoogle Scholar
  22. 22.
    Niu Z, Wang J, Zou H, Yang C, Huang W, Jin L (2015) Common MIR146A polymorphisms in Chinese ankylosing spondylitis subjects and controls. PLoS One 10(9):e0137770.  https://doi.org/10.1371/journal.pone.0137770 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ma X, Wu F, Xin L, Su G, He F, Yang Y, Sun J, Liu Z (2016) Differential plasma microRNAs expression in juvenile idiopathic arthritis. Mod Rheumatol 26(2):224–232.  https://doi.org/10.3109/14397595.2015.1060663 PubMedGoogle Scholar
  24. 24.
    Yang J, Gao T, Tang J, Cai H, Lin L, Fu S (2013) Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. Mol Cell Biochem 381(1-2):9–15.  https://doi.org/10.1007/s11010-013-1677-8 CrossRefPubMedGoogle Scholar
  25. 25.
    Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA (2010) MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16(8):909–914.  https://doi.org/10.1038/nm.2186 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gordon DA (1977) Diagnosis and management of ankylosing spondylitis. Can Fam Physician 23:80–82PubMedPubMedCentralGoogle Scholar
  27. 27.
    Park MH, Park E, Kim HJ, Na HS, Chung J (2016) Porphyromonas gingivalis-induced miR-132 regulates TNFalpha expression in THP-1 derived macrophages. Spring 5(1):761.  https://doi.org/10.1186/s40064-016-2363-6 CrossRefGoogle Scholar
  28. 28.
    Liu F, Li Y, Jiang R, Nie C, Zeng Z, Zhao N, Huang C, Shao Q, Ding C, Qing C, Xia L, Zeng E, Qian K (2015) miR-132 inhibits lipopolysaccharide-induced inflammation in alveolar macrophages by the cholinergic anti-inflammatory pathway. Exp Lung Res 41(5):261–269.  https://doi.org/10.3109/01902148.2015.1004206 CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang JX, Zhai JF, Yang XT, Wang J (2016) MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFbeta1/Smad 2 in human non-small cell lung cancer. Eur Rev Med Pharmacol Sci 20(18):3793–3801PubMedGoogle Scholar
  30. 30.
    Li YQ, Wang JY, Qian ZQ, Li YL, Li WN, Gao Y, Yang DL (2017) Osthole inhibits intimal hyperplasia by regulating the NF-kappaB and TGF-beta1/Smad2 signalling pathways in the rat carotid artery after balloon injury. Eur J Pharmacol 811:232–239.  https://doi.org/10.1016/j.ejphar.2017.06.025 CrossRefPubMedGoogle Scholar
  31. 31.
    Kim HY, Kwon HY, Ha Thi HT, Lee HJ, Kim GI, Hahm KB, Hong S (2016) MicroRNA-132 and microRNA-223 control positive feedback circuit by regulating FOXO3a in inflammatory bowel disease. J Gastroenterol Hepatol 31(10):1727–1735.  https://doi.org/10.1111/jgh.13321 CrossRefPubMedGoogle Scholar
  32. 32.
    Nahid MA, Yao B, Dominguez-Gutierrez PR, Kesavalu L, Satoh M, Chan EK (2013) Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212. J Immunol 190(3):1250–1263.  https://doi.org/10.4049/jimmunol.1103060 CrossRefPubMedGoogle Scholar
  33. 33.
    Kim HR, Hwang SJ, Shin CH, Choi KH, Ohn T, Kim HH (2017) SRSF3-regulated miR-132/212 controls cell migration and invasion by targeting YAP1. Exp Cell Res 358(2):161–170.  https://doi.org/10.1016/j.yexcr.2017.06.009 CrossRefPubMedGoogle Scholar
  34. 34.
    Sun XY, Zhang J, Niu W, Guo W, Song HT, Li HY, Fan HM, Zhao L, Zhong AF, Dai YH, Guo ZM, Zhang LY, Lu J, Zhang QL (2015) A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 168B(3):170–178.  https://doi.org/10.1002/ajmg.b.32292 CrossRefPubMedGoogle Scholar
  35. 35.
    Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59(4):901–908.  https://doi.org/10.1124/mol.59.4.901 CrossRefPubMedGoogle Scholar
  36. 36.
    Iguchi G, Chrysovergis K, Lee SH, Baek SJ, Langenbach R, Eling TE (2009) A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2. Cancer Lett 282(2):152–158.  https://doi.org/10.1016/j.canlet.2009.03.006 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lee SH, Krisanapun C, Baek SJ (2010) NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 31(4):719–728.  https://doi.org/10.1093/carcin/bgq016 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Shim M, Eling TE (2005) Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 280(19):18636–18642.  https://doi.org/10.1074/jbc.M414613200 CrossRefPubMedGoogle Scholar
  39. 39.
    Snyder MJ, Bepko J, White M (2014) Acute pericarditis: diagnosis and management. Am Fam Physician 89(7):553–560PubMedGoogle Scholar
  40. 40.
    Hart FD (1958) Ankylosing spondylitis. Br Med J 2(5104):1082–1083.  https://doi.org/10.1136/bmj.2.5104.1082 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Carson JL, Willett LR (1993) Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence. Drugs 46(Suppl 1):243–248.  https://doi.org/10.2165/00003495-199300461-00063 CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Tuan-Mao Guo
    • 1
  • Yong Yan
    • 2
  • Wei-Ning Cao
    • 1
  • Qiang Liu
    • 3
  • Hai-Yun Zhu
    • 4
  • Lan Yang
    • 4
  • Mai-Cang Gao
    • 5
  • Yan-Li Xing
    • 6
  1. 1.The Second Department of OrthopaedicsXianyang Central HospitalXianyangPeople’s Republic of China
  2. 2.The Second Department of OrthopaedicsShaanxi Traditional Chinese Medicine HospitalXi’anPeople’s Republic of China
  3. 3.The First Department of OrthopaedicsXianyang Central HospitalXianyangPeople’s Republic of China
  4. 4.Xianyang Central HospitalXianyangPeople’s Republic of China
  5. 5.Department of Critical Care Medicine, the First Affiliated HospitalShaanxi University of Chinese MedicineXianyangPeople’s Republic of China
  6. 6.Pharmaceutical Preparation SectionXianyang Central HospitalXianyangPeople’s Republic of China

Personalised recommendations